Eva Herrmann

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. ncbi Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Antivir Ther 11:371-6. 2006
  2. ncbi Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
  3. ncbi The kinetics of hepatitis C virus
    Eva Herrmann
    Saarland University, Faculty of Medicine, Internal Medicine II, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 18:339-42. 2006
  4. ncbi Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    J Infect Dis 192:1710-9. 2005
  5. ncbi Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
  6. ncbi Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C
    Bernd Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, D 66421 Homburg Saar, Germany
    J Leukoc Biol 80:298-308. 2006
  7. ncbi Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease
    Tanja M Raedle-Hurst
    Second Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 20:865-73. 2008
  8. ncbi Growth differentiation factor 15--an early marker of abnormal function of the Fontan circuit in patients with univentricular hearts
    Tanja M Raedle-Hurst
    Department of Pediatric Cardiology, Saarland University Hospital, Homburg Saar, Germany
    Am Heart J 160:1105-12. 2010
  9. ncbi Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis
    Mireen Friedrich-Rust
    Department of Internal Medicine II, Saarland University Hospital, Kirrbergerstrasse, Bldg 41, Homburg Saar 66421, Germany
    AJR Am J Roentgenol 188:758-64. 2007
  10. ncbi Assessment of left ventricular dyssynchrony and function using real-time 3-dimensional echocardiography in patients with congenital right heart disease
    Tanja M Raedle-Hurst
    Department of Pediatric Cardiology, Saarland University Hospital, Homburg Saar, Germany
    Am Heart J 157:791-8. 2009

Collaborators

Detail Information

Publications38

  1. ncbi Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Antivir Ther 11:371-6. 2006
    ..Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments...
  2. ncbi Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
    ..However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response...
  3. ncbi The kinetics of hepatitis C virus
    Eva Herrmann
    Saarland University, Faculty of Medicine, Internal Medicine II, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 18:339-42. 2006
    ..The main aims of analysing hepatitis C viral kinetics include the efficient comparison of different treatment regimens, prediction of virological response, and conclusions on antiviral mechanisms of therapy...
  4. ncbi Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    J Infect Dis 192:1710-9. 2005
    ..Mutations in nonstructural (NS) hepatitis C virus (HCV) proteins enhance replication in HCV-1a/b replicons. The prevalence of such mutations and their clinical significance in vivo are unknown...
  5. ncbi Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
    ....
  6. ncbi Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C
    Bernd Kronenberger
    Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, D 66421 Homburg Saar, Germany
    J Leukoc Biol 80:298-308. 2006
    ..033). Lymphocyte subsets show different patterns of CD81 response before and during antiviral treatment, which are associated with administration of IFN-alpha and antiviral response...
  7. ncbi Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease
    Tanja M Raedle-Hurst
    Second Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 20:865-73. 2008
    ..The aim of the study was to validate the N-terminal propeptide of the brain natriuretic peptide (NT-proBNP) in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease...
  8. ncbi Growth differentiation factor 15--an early marker of abnormal function of the Fontan circuit in patients with univentricular hearts
    Tanja M Raedle-Hurst
    Department of Pediatric Cardiology, Saarland University Hospital, Homburg Saar, Germany
    Am Heart J 160:1105-12. 2010
    ..The aim of the study was to evaluate growth differentiation factor 15 (GDF-15), a marker of various stress pathways in the heart and extracardiac tissues...
  9. ncbi Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis
    Mireen Friedrich-Rust
    Department of Internal Medicine II, Saarland University Hospital, Kirrbergerstrasse, Bldg 41, Homburg Saar 66421, Germany
    AJR Am J Roentgenol 188:758-64. 2007
    ..Here, we investigated a novel approach for noninvasive assessment of liver fibrosis using sonography-based real-time elastography, which can be performed with conventional ultrasound probes during a routine sonography examination...
  10. ncbi Assessment of left ventricular dyssynchrony and function using real-time 3-dimensional echocardiography in patients with congenital right heart disease
    Tanja M Raedle-Hurst
    Department of Pediatric Cardiology, Saarland University Hospital, Homburg Saar, Germany
    Am Heart J 157:791-8. 2009
    ..The aim of the study was to assess LVD according to a novel global systolic dyssynchrony index (SDI) derived from real-time 3-dimensional echocardiography in patients after repaired CRHD...
  11. ncbi Structural and functional comparison of the non-structural protein 4B in flaviviridae
    Christoph Welsch
    Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg Saar, Germany
    J Mol Graph Model 26:546-57. 2007
    ..Important structural and functional properties of NS4B are predicted with implications for ER-stress response, altered gene expression and replication efficacy...
  12. ncbi Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Eva Herrmann
    Medizinische Klinik und Poliklinik, Innere Medizin II, , Homburg/Saar, Germany
    Hepatology 37:1351-8. 2003
    ..This finding suggests that combination treatment leads to a better restoration of the patient's immune response...
  13. ncbi Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses
    Christoph Sarrazin
    Medizinische Klinik II, Johann Wolfgang Goethe Universitat, 60590 Frankfurt am Main, Germany
    J Virol 76:11079-90. 2002
    ..For improvement of mutational analysis, a refined specific functional data test procedure is proposed...
  14. ncbi Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, , Campus Virchow-Klinikum, , Berlin, Germany
    Hepatology 37:600-9. 2003
    ..This algorithm recognizes 53.7% of nonresponders previously identified at week 24 of treatment...
  15. ncbi Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...
  16. ncbi Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C
    Bernd Kronenberger
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe UniversitRt, Frankfurt Main, Germany
    Antivir Ther 12:779-87. 2007
    ..Cell death during antiviral therapy of patients with chronic hepatitis C is not well understood...
  17. ncbi Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin
    Francesca Dal Pero
    Venetian Institute for Molecular Medicine, Padova, 35129, Italy
    J Infect Dis 196:998-1005. 2007
    ..Little is known about NS5A sequences of HCV-1a. We investigated whether genetic variability of HCV-1a NS5A correlates with the early HCV kinetics during treatment...
  18. ncbi Reply to Real-time elastography in the assessment of liver fibrosis
    Mireen Friedrich-Rust
    AJR Am J Roentgenol 190:W164. 2008
  19. ncbi Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C
    Ulrike Mihm
    , , Kirrberger Str, 66421 Homburg/Saar, Germany
    Antivir Ther 11:507-19. 2006
    ..Non-responders with HCV-1b infection showed higher numbers of non-conservative aa variations within HCV p7 than responders, irrespective of the application of amantadine...
  20. ncbi Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy
    Wolf Peter Hofmann
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:921-30. 2007
    ..Ribavirin acts as an RNA virus mutagen in vitro, thereby leading to error catastrophe. However, data in CHC are controversial...
  21. ncbi Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
    Thomas Berg
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat, Berlin, Germany
    Hepatology 37:1359-67. 2003
    ....
  22. ncbi Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels
    Bernd Kronenberger
    , , Homburg/Saar, Germany
    Hepatology 40:1442-9. 2004
    ..These data show that virological response in patients with chronic hepatitis C is less associated with baseline ALT than with GGT levels...
  23. ncbi Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue
    Wolf Peter Hofmann
    , , 66421 Homburg, Germany
    J Clin Virol 32:289-93. 2005
    ..019). CONCLUSION: Our results suggest that both the extraction and amplification step of the TMA-based assay contribute to the higher sensitivity compared with standard RT-PCR...
  24. ncbi Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    Michael von Wagner
    , Homburg/Saar, Germany
    Gastroenterology 129:522-7. 2005
    ..In patients infected by HCV-3 (high viral load), longer treatment may be necessary...
  25. ncbi Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy
    Kwok H Tang
    Institute of Hepatology, University College London, 69-75 Chenies Mews, London. WC1E 6HX, UK
    J Hepatol 43:776-82. 2005
    ..Enhancement of antiviral T-cell reactivity requires rapid viraemia clearance, rather than immunostimulation alone...
  26. ncbi New kinetic models for the hepatitis C virus
    Alan S Perelson
    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87525, USA
    Hepatology 42:749-54. 2005
    ....
  27. ncbi Dynamics of hepatitis C virus infection
    Stefan Zeuzem
    Department of Medicine, University Hospital Homburg/Saar, Germany
    Ann Hepatol 1:56-63. 2002
    ..This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase...
  28. ncbi Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study
    Markus Cornberg
    Abt. Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
    J Hepatol 44:291-301. 2006
    ..However, motivation and compliance are requisites and a CIFN induction is not required...
  29. ncbi Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C
    Ulrike Mihm
    , , Kirrberger Strasse, D-66421 Homburg/Saar, Germany
    J Hepatol 40:845-52. 2004
    ..Thus, the conclusion from in vitro studies that the upregulation of interleukin-8 by the hepatitis C virus contributes to the inhibition of the antiviral actions of interferon-alpha may also be applicable in vivo...
  30. ncbi Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
    Michael von Wagner
    Johann Wolfgang Goethe Universitat, Frankfurt, Main, Germany
    Hepatology 48:1404-11. 2008
    ..CONCLUSION: In this large placebo-controlled multicenter study, amantadine even at a dose of 400 mg/day did not improve virological response rates of peginterferon alfa-2a and ribavirin in patients with chronic genotype HCV-1 infection...
  31. ncbi Performance of transient elastography for the staging of liver fibrosis: a meta-analysis
    Mireen Friedrich-Rust
    Department of Internal Medicine I, J W Goethe University Hospital, Frankfurt, Germany
    Gastroenterology 134:960-74. 2008
    ..A meta-analysis was performed to assess the overall performance of transient elastography for the diagnosis of liver fibrosis and to analyze factors influencing the diagnostic accuracy...
  32. ncbi Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers
    Mireen Friedrich-Rust
    Department of Internal Medicine, JW Goethe University Clinic, Frankfurt, Germany
    J Thorac Cardiovasc Surg 135:560-7. 2008
    ..Therefore, early detection of fibrosis is essential to identify patients at risk. Transient elastography has been evaluated for noninvasive staging of liver fibrosis in a multitude of studies...
  33. ncbi Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B
    Martijn J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Antivir Ther 12:1285-94. 2007
    ..HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-alpha2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha2b monotherapy...
  34. ncbi Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
    Bernd Kronenberger
    Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt M, Germany
    Eur J Gastroenterol Hepatol 19:639-46. 2007
    ..The aim of this study was to investigate whether amantadine reduces deterioration of quality of life in patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin...
  35. ncbi Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes
    Wolf Peter Hofmann
    Blood 104:1228-9. 2004
  36. ncbi The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells
    George Koutsoudakis
    Department Molecular Virology, University Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    J Virol 81:588-98. 2007
    ..Together these data indicate that a high density of cell surface-exposed CD81 is a key determinant for productive HCV entry into host cells...
  37. ncbi Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy
    Ulrike Mihm
    , , Kirrberger Str, 66421 Homburg/Saar, Germany
    J Hepatol 43:217-24. 2005
    ....
  38. ncbi First-phase parameters in hepatitis C viral kinetics
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, University Hospital Homburg/Saar, Germany
    J Viral Hepat 9:332-3. 2002